Management attributed the 2025 earnings shortfall to significant headwinds concentrated in just three surgical hospital markets, rather than systemic enterprise-wide issues.

Performance was pressured by a sharper-than-expected shift in payer mix, as newly recruited physicians served more Medicare patients and ramped slower than historical cohorts.

A 'physician transition' dynamic occurred where retiring high-volume commercial surgeons were replaced by doctors with lower commercial mix, impacting top-line margins.

Operational deleverage occurred because labor and anesthesia coverage costs did not adjust quickly enough to the changing volume and payer mix in the second half of the year.

High-acuity procedure growth remained a bright spot, with total joint replacements growing 19% year-to-date, supported by the deployment of 74 surgical robots.

The company is shifting toward a 'short-stay' surgical strategy, leading to the divestiture or partnership of larger surgical hospitals that no longer fit the core model.

Management acknowledged execution gaps and has installed new leadership, including a new COO, to stabilize the underperforming hospital markets.

Initial 2026 guidance takes a 'measured and conservative' approach, embedding the identified headwinds from physician transitions and anesthesia costs into the baseline.

The company expects to reach a resolution on a 'key part' of its portfolio optimization effort within the first half of 2026 to accelerate balance sheet improvement.

M&A strategy remains focused on a $200 million annual deployment target, though management emphasized a disciplined approach over meeting specific timing goals.

Future revenue reporting will be impacted by the transition of consolidated facilities to non-consolidated joint ventures, such as the Baylor Scott & White partnership.

Long-term growth assumes a 12 to 18-month build cycle for de novo facilities, with an additional year required to reach breakeven performance.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

The Baylor Scott & White joint venture in Bryan, Texas, serves as a template for future portfolio optimization, prioritizing strategic alignment over consolidation.

Anesthesia subsidy pressure, previously managed in ASCs, has now migrated to surgical hospitals with higher Medicare populations, creating a new margin headwind.

Delayed net capital deployment in 2025 contributed to the revenue miss, as M&A activity was back-end weighted and slightly below the $200 million target.

Management is planning an Investor Day to be timed with a 'validating milestone' in the portfolio review process to provide a long-term composition update.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.